VIP and neoplasm: The analysis of tumor-infiltrating leukocytes demonstrated that VIP antagonist did not significantly change the population of macrophages (Fig. 3B), M1 and M2 macrophages (Fig. 3C), as well as NK cells (Fig. 3D) in the implanted tumors compared with the controls.